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Cells.
Monocytes and PBL were isolated and cultured as noted b e f~r e .~ In brief, monocytes were isolated by sequential ficoll-sodium diatrizoate and Percoll gradients with subsequent adherence to cultureware plastic and then cultured in Dulbecco's modified Eagle medium (GIBCO, Grand Island, NY) with 10% unheated human serum. Mitogen-simulated PBL were prepared as noted before using anti-CD3 and anti-CD28 antibomes with interleukin-2 (IL-2).6 Jurkat, CEM, HL-60, and U937 cells were from American Type Culture Collection (Baltimore, MD). They were cultured in RPMI-1640 with 10% fetal bovine serum (Hyclone, Logan, UT). OM-10.1 cells were a gift from Dr Clay Smith (Duke University, Durham, NC). All experiments were performed in conventional tissue culture laboratories under reduced light but not in absolute darkness.
Viruses, viral reverse transcriptase (RT) assay, gp120-CD4 binding assay, p24 assay, polymerase chain reaction (PCR) assays, and interferon-cr (IFN-a) assays. The monocytotropic strain HIV-IBaL and the lymphocytotropic strain HIV-1-LA1 are maintained in our laboratory as noted before.' RT was measured as described before' using a phosphoimager device for quantification. Binding of recombinant gp120 to recombinant soluble CD4 was performed in microtiter plates using reagents from Genentech (South San Francisco, CA). In brief, wells were first coated with 200 ng of gp120 and CD4 (40 ng in 0.1 mL of phosphate-buffered saline [PBS]) was added with varying amounts of the designated cobalamins to allow binding. Bound CD4 was then detected using a horseradish peroxidase-conjugated anti-CD4 monoclonal antibody. HIV-I p24 antigen was measured using a capture enzyme-linked immunosorbent assay (ELISA) method (Coulter, Inc, Hialeah, FL). The PCR-based assay for newly synthesized viral DNA was performed as noted &fore.' In brief, cells were inoculated with DNAse-treated virus alone or in Cobalamins did not modify binding of gp120 to CD4 or block early steps in viral life cycle, inhibit reverse transcriptase, inhibit induction of HIV-1 expression from cells with established or latent infection, or modify monocyte interferon-cu production. Because of the ability to achieve high blood and tissue levels of cobalamins in vivo and the general lack of toxicity, cobalamins should be considered as potentially useful agents for the treatment of HIV-1 infection. This is a US government work. There are no restrictions on its use. the presence of the appropriate cobalamin. Cells were then washed and cultured in medium for 20 hours with 10 pg/mL anti-CD4 antibody (Leu3A from Becton Dickinson, Mountain View, CA) to prevent any further viral entry. This time period simulates a single round of virus infection. Cellular lysates were prepared, and total cellular DNA was subjected to 38 cycles of PCR amplification using primers that flank the nef gene' to generate an approximately 1.2-kb HIV-l -specific PCR product. P-Globin-specific primers were used to assure approximate equal numbers of cells in the samples. IFN-(Y assays were performed using the specific enzyme-linked immunosorbent assay (ELISA) BioSource International (Camarillo, CA), an assay that can detect IFN-a down to a minimum of 10 pg/ mL.
Cobalamins. Cobalamins were from Sigma Chemical CO (St Louis, MO) or ICN (Costa Mesa, CA); cobalamins from either source gave comparable results. The cobalamins had extremely low endotoxin content, as determined by Limulus amebocyte lysate testing (Whittaker Bioproducts, Walkersville, MD). When tested as a 3 mmol/L solution, the cobalamins had less than 0.25 EU/mL.
RESULTS
OH-Cbl, Me-Cbl, Ado-Cbl, and cyanocobalamin (CN-CM) were not toxic for MO, PBL, or cells of the human leukemia cell lines Jurkat, CEM, HL-60, or U937 at concentrations 1 , OOO pmol/L (Fig 1) . When added to the cultures of monocytes or PBL at the time of viral inoculation and left in throughout the culture period, there was potent inhibition of productive infection as judged by supernatant medium RT not absolute darkness) significant fractions of Me-Cbl and Ado-Cbl were converted to OH-Cbl in vitro.
Although OH-Cbl. Me-Cbl, and Ado-Cbl inhibited HIV-1 infection of these primary, normal leukocytes, they had much less inhibitory effect on the infection of cells of the human T lymphoblast lines Jurkat and CEM, the myeloblastic line HL-60, or the monoblastic line U937 (Fig ID) . The inhibition of productive infection was not strain specific-OH-Cbl, Me-Cbl, and Ado-Cbl inhibited infection of monocytes with the monocytotropic strains HIV-I -BaL or HIV- If monocytes were pretreated with 250 pmol/L OH-Cbl for 24 hours, washed well, and then inoculated with HIV-I-BaL, the OH-Cbl-treated cells were protected against HIV-I infection (Fig 3A) . However, the degree of inhibition was less than that in cultures in which OH-Cbl was present throughout the culture period. If monocytes were incubated simultaneously with 250 pmol/L OH-Cbl and HIV-I for 4 hours, washed, and then cultured for I O days. OH-Cbltreated cells expressed less viral RT (Fig 3B) . When monocytes were inoculated with HIV-I and cultured for 6 days (a time at which they displayed multinucleated giant cell formation and RT production), washed thoroughly. and then cultured for 10 more days with 250 pmol/L OH-Cbl, there was no inhibition of their subsequent production of RT ( Fig  3C) . To determine if OH-Cbl would inhibit the ability of latently infected leukemia cells to produce RT after stimulation with tumor necrosis factor (TNF), we treated OM-10.1 cells (an HL-60 cell line with stably integrated proviral HIV-1)"' with 500 U/mL TNF (with varying amounts of OHCbl). OH-Cbl caused only slight decreases in the expression of the induced viral RT (Fig 3D) . The inability of the cohnlamins to effectively inhibit HIV-I production in previously infected monocytes and in latently infcctctl Icrlkcmi:l c d h is similar to that seen when using drugs such alr thc !U inhibitors zidovudine, didanosine. and zalcitibine."."
HIV-I binds to cells principally via interaction with cell membrane CD4.l"'' Other investigators have shown that heme and various porphyrins inhibit HIV-I infection'.' and that this inhibition generally parallels the compounds' abilities to block gpl20-CD4 binding.' To determine if cobalamins modified the binding of HIV-1 gpl20 to CD4. we tested the ability of CN-Cbl, OH-Cbl, Me-Cbl, or Ado-Cbl to block binding of recombinant CD4 with gp120 from HIV-I -LA1 or HIV-I-MN (Fig 4A and B) . None of the cobalamins inhibited binding. Likewise, neither CN-Chl nor OH-Chl inhibited early steps in the life cycle of HIV-I -BaL in monocytes (viral-cell fusion. viral entry. and reverse transcription: Fig 4C) .
It was possible that the cobalamins induced an intrinsic HIV-I resistance system (eg, induction of IFN-a)'" within the cells. To determine if cobalamins might induce cellular production of IFN-a (which could then render cells resistant to HIV-I infection), we treated monocytes with 15 to 500 pmol/L CN-Cbl or OH-Cbl for 3 days and measured IFN-a in the supernatant media using a sensitive ELISA. IFN-a production was not induced by the cobalamin treatments; eg, the supernatant fluid of monocytes cultured 3 days in media with 10% human serum contained 71 2 I pg/mL IFN-a, whereas that of monocytes cultured in media with 10% human serum and 500 pmol/L OH-Cbl contained 74 +-5 pg/mL and that of monocytes cultured in media with 10% human serum and 500 pmol/L CN-Cbl contained 71 ? 1 pg/mL. Likewise, monocytes inoculated with HIV- 1-BaL cultured with or without CN-Cbl or OH-Cbl did not vary significantly in their IFN-a production (data not shown).
DISCUSSION
Cobalamins are polycyclic compounds containing a cobalt within the corrin ring, an upper axial ligand for the cobalt (eg, cyano-, hydroxo-, methyl-, or adenosyl-), and a dimethylbenzimidazole nucleotide moiety that forms the lower axial cobalt ligand. Cobalamins are absorbed from the gut into the blood by processes that require the proteins intrinsic factor and transcobalamin I1 (TC-II).','' They are transported in the blood bound to TC-11; the Cbl-TC-I1 complex enters cells after binding to TC-I1 membrane receptors. CN-Cbl (vitamin B,*) is a relatively nonreactive, stabilized cobalamin that is not found normally in the body. It is used pharmacologically for the treatment of B l z deficiency states in humans. In vivo, cyanide is removed from the cobalt with production HIV-I infection or to gp120 and that the locally produced NO might be directly cytotoxic to neural cells. Individuals with HIV-1 infection and central nervous system (CNS) abnormalities have been noted to have disturbances in their CNS methyl group metabolism, as judged by cerebrospinal fluid st~dies,'~.~' indicating a possible functional CNS deficiency of cobalamins. Also, restoration of cobalamin levels in humans appears to improve information processing in HIV-l -infected subjects.42 Me-Cbl has been noted to protect against NO-mediated neuronal toxicity in vitro." It is possible that locoregional NO production in the nervous system could serve to modify cobalamins and to create a relative functional deficiency of vitamin B,> in selected regions of the nervous system. Because cobalamins might inhibit productive HIV-I infection in vivo, local CNS vitamin B,, deficiency could contribute to neuropathology and cause a local enhancement of HIV-I infection. Although not addressed experimentally in our work here. it is also possible that neuropathology associated with vitamin B,2 deficiency in those without HIV-1 infection could be related to nervous system deficiency of a compound (cobalamin) capable of inhibiting neurotoxicity mediated by NO produced physiologically during normal nervous tissue function.
Further work will be required to precisely determine the mechanisms by which cobalamins inhibit HIV-l infection and whether this inhibition extends to other HIV strains and to primary HIV-l isolates. Other cobalamin analogues may be discovered with more potent anti-HIV-1 activity. It is important to note that cobalamins used therapeutically in humans are generally nontoxic. OH-Cbl has been administered in very high doses to humans for treatment of cyanide poisoning.13 Noted side effects are minimal and include redcolored urine and transient high blood pressure (presumably because of OH-Cbl binding and quenching of NO). Based on our in vitro findings, we propose that experimental treatment of HIV-l-infected patients with high doses of OHCbl might (in a nontoxic fashion) inhibit HIV-I infection in vivo.
